Breast Cancer Clinical Trial
Mass Response of Malignant Fluid Cells as a Biomarker for Rapid Therapy Guidance
Summary
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from malignant fluids such as pleural effusions and ascites.
Eligibility Criteria
Inclusion Criteria:
Patient is ≥18 years of age
Written Informed Consent provided by patient
Diagnosis of any kind of carcinoma
Malignant fluid (e.g. pleural effusion or ascites) drainage is clinically indicated as part of SOC
Proceeding onto therapy for treatment
Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)
Exclusion Criteria:
Lack of informed consent
Unable to obtain sufficient sample
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?